Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Fry

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Clinical Pharmacology in Drug Development|September 19, 2025
A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participantsHakim Charfi, Benedetta Massetto, Megan Fitzgerald, et al.
The New England Journal of Medicine|November 19, 2015
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge StudyJohn P DeVincenzo, Matthew W McClure, Julian A Symons, et al.
Antiviral Therapy|April 29, 2022
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteersThomas N Kakuda, Jeysen Z Yogaratnam, Christopher Westland, et al.
The New England Journal of Medicine|February 28, 2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BPatrick Marcellin, Ting-Tsung Chang, Seng Gee Lim, et al.
The Journal of Infectious Diseases|July 28, 2018
Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge StudyJeysen Yogaratnam, Jennifer Rito, Thomas N Kakuda, et al.
Plos One|July 19, 2023
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic resultsAbbie Oey, Matthew McClure, Julian A Symons, et al.
The New England Journal of Medicine|February 28, 2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humansKashyap Patel, Carl M Kirkpatrick, Keith A Nieforth, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2026
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trialMan-Fung Yuen, Kosh Agarwal, Alina Jucov, et al.
Pharmacology Research & Perspectives|May 9, 2018
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjectsThomas N Kakuda, Matthew W McClure, Christopher Westland, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Clinical Pharmacology in Drug Development|September 19, 2025
A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participantsHakim Charfi, Benedetta Massetto, Megan Fitzgerald, et al.
The New England Journal of Medicine|November 19, 2015
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge StudyJohn P DeVincenzo, Matthew W McClure, Julian A Symons, et al.
Antiviral Therapy|April 29, 2022
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteersThomas N Kakuda, Jeysen Z Yogaratnam, Christopher Westland, et al.
The New England Journal of Medicine|February 28, 2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BPatrick Marcellin, Ting-Tsung Chang, Seng Gee Lim, et al.
The Journal of Infectious Diseases|July 28, 2018
Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge StudyJeysen Yogaratnam, Jennifer Rito, Thomas N Kakuda, et al.
Plos One|July 19, 2023
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic resultsAbbie Oey, Matthew McClure, Julian A Symons, et al.
The New England Journal of Medicine|February 28, 2003
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BStephanos J Hadziyannis, Nicolaos C Tassopoulos, E Jenny Heathcote, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humansKashyap Patel, Carl M Kirkpatrick, Keith A Nieforth, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2026
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trialMan-Fung Yuen, Kosh Agarwal, Alina Jucov, et al.
Pharmacology Research & Perspectives|May 9, 2018
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjectsThomas N Kakuda, Matthew W McClure, Christopher Westland, et al.
Pageof 4